Should polypharmacy dissuade treatment optimization in heart failure?

No.

Hot off the press data suggest efficacy is sustained (maybe even better!) among those on a large # of background medicines.

#ARNI in #PARAGONHF (L) & #SGLT2i in #DELIVER (R)

👇🏾

Don’t miss “Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Randomized Clinical Trial” published in @jamacardio and presented at #ACC24 .

ja.ma/3PWt9fq

Alexander Peikert scottdavidsolomon orlyvardeny

The benefits of semaglutide #T2D in HFpEF do not appear to be strictly related to #weightloss and remain evident on top of SGLT2i (32.8%) and mineralocorticoid receptor antagonists (32.5%) nejm.org/doi/full/10.10…

Outstanding #ACC24 American College of Cardiology all around with a wealth of practice-changing science. Congratulations to all the investigators. Great to see everyone in ATL.

Especially proud and grateful to be able to work with this crew!

An outstanding achievement by the DEDICATE-DZHK6 study team and more certainty for patients about treatment choices.
Thanks to all who participated: Deutsche Gesellschaft für Kardiologie Deutsche Herzstiftung UKE Hamburg DGTHG
#CardioTwitter

Original Article: Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction (REDUCE-AMI) nej.md/4akVhRx

Editorial: Routine Beta-Blockers in Secondary Prevention — On Injured Reserve nej.md/3vQKorv

American College of Cardiology #ACC24

Does the effect of flu vaccine vary dependent on immune response? Study examined the antibody response to high- vs. standard dose flu vaccine and its associations with clinical outcomes. LBCT at #ACC24 ja.ma/3vPc7J7 Alexander Peikert scottdavidsolomon orlyvardeny

Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Trial, just presented at #ACC24 , is free to read online from JAMA Cardiology ja.ma/3TKazbm

#ACC24 #JACCHF leading edge commentary on DAPA-MI & EMPACT-MI trials complement the current evidentiary base to further our understanding of the role of #SGLT2i on the dev. of HF & clinical events when initiated early after #cvAMI . bit.ly/3VIw52U Alexander Peikert Muthu Vaduganathan

Looking forward to great science and meeting friends @ #ACC24 in Atlanta!

Delighted to share our latest insights on abdominal #obesity in #HFpEF and immune response to #flu vaccines in high-risk #CVD

scottdavidsolomon Muthu Vaduganathan orlyvardeny

FDA clearance for Us2.v2, featuring 45 automated echo parameters, including strain analysis, marking a significant stride in medical innovation!

us2.ai/us2-ai-receive…

.Brigham and Women’s Research Clinical Trials Outcomes Center American College of Cardiology #ACC24

Incredibly proud of this diverse group of talented investigators, featuring
🔥 Young Investigator Award Session
🔥 Highlighted Original Research
🔥 >10 Simultaneous Publications

Excited to see everyone in ATL!

Global P3 #BalanceDHF testing new combo #MRmodulator balcinrenone & #SGLT2i dapagliflozin

☑️ Unique Rx: balci/dapa designed to maximize safety
☑️ Broad highrisk cohort: HF across LVEF, CKD, recent worsening HF
☑️ Best SoC comparator: active control design
clinicaltrials.gov/study/NCT06307…

New data in European Society of Cardiology Journals #EJHF from #DAPAHF & #DELIVER by Alexander Peikert

#SGLT2i dapagliflozin shows consistent protection against hospitalizations & death in HF and prior MI

Will #SGLT2i modify risk early after acute MI? Stay tuned for #EMPACTMI at #ACC24 !

onlinelibrary.wiley.com/doi/full/10.10…

#cardiology #cardiotwitter #heartfailure #obesity

Day 3 at #CVCT2023 . Should patients be treated with #SGLT2i post MI? Fantastic deep dive in the latest evidence on #SGLT2i therapy post MI at CVCT - CardioVascular Clinical Trialists

BiykemBozkurt Darren McGuire Javed Butler Muthu Vaduganathan scottdavidsolomon Faiez ZANNAD

So good to be in the midst of good people!

#CVCT2023
CVCT - CardioVascular Clinical Trialists
Women as One

Simultaneous targeting of #GIP / #GLP1 / #glucagon receptors may reduce weight to a similar extent as #bariatric surgery! Lou Aronne highlights the impressive potential of the latest developments in anti-obesity therapeutics at #CVCT2023 CVCT - CardioVascular Clinical Trialists

Second day of #CVCT23 . Obesity moves center stage at CVCT - CardioVascular Clinical Trialists. Session 2/2 and the discussion continues with Javed Butler focusing on #obesity drugs in #HFrEF